Standout Papers

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patie... 1997 2026 2006 2016 4.6k
  1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. (1997)
    Howard A. Burris, Malcolm J. Moore et al. Journal of Clinical Oncology
  2. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (2007)
    Malcolm J. Moore, David Goldstein et al. Journal of Clinical Oncology
  3. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer (2008)
    Christos S. Karapetis, Shirin Khambata‐Ford et al. New England Journal of Medicine
  4. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer (2000)
    Leonard B. Saltz, John V. Cox et al. New England Journal of Medicine
  5. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study (2000)
    Hans von der Maase, Steen Werner Hansen et al. Journal of Clinical Oncology
  6. Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer (2003)
    Christine Ribic, Daniel J. Sargent et al. New England Journal of Medicine
  7. Cetuximab for the Treatment of Colorectal Cancer (2007)
    Derek J. Jonker, Chris J. O’Callaghan et al. New England Journal of Medicine
  8. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer (2005)
    Hans von der Maase, Lisa Sengeløv et al. Journal of Clinical Oncology
  9. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial (2014)
    Camilla Zimmermann, Nadia Swami et al. The Lancet
  10. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. (1996)
    I. F. Tannock, David Osoba et al. Journal of Clinical Oncology
  11. Advanced pancreatic carcinoma: current treatment and future challenges (2010)
    Anastasios Stathis, Malcolm J. Moore Nature Reviews Clinical Oncology
  12. Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer (2009)
    Eric Van Cutsem, Walter L. Vervenne et al. Journal of Clinical Oncology

Immediate Impact

3 by Nobel laureates 13 from Science/Nature 129 standout
Sub-graph 1 of 18

Citing Papers

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
2023 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
9 intermediate papers

Works of Malcolm J. Moore being referenced

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
2000 Standout
and 9 more

Author Peers

Author Last Decade Papers Cites
Malcolm J. Moore 24529 10385 9275 354 36.2k
Leonard B. Saltz 27418 9385 10097 533 37.4k
Patrick Maisonneuve 16762 7026 11821 555 40.6k
Al B. Benson 18591 8504 8507 487 30.3k
John D. Hainsworth 21144 12105 5165 623 36.4k
James L. Abbruzzese 25539 8411 7792 507 42.6k
Bengt Glimelius 29523 9594 17485 690 40.5k
Richard M. Goldberg 23508 8152 6742 526 32.6k
Robert A. Wolff 21227 8251 9068 455 28.2k
Richard Pazdur 19104 9902 3689 582 36.2k
Michel Ducreux 25207 10305 11207 612 36.6k

All Works

Loading papers...

Rankless by CCL
2026